{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T02:13:41Z","timestamp":1648606421222},"reference-count":21,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown remarkable efficacy in patients with refractory\/relapsed HL, also demonstrating an acceptable safety profile. However, due to effects on T-cell activity, the use of PD-1 inhibitors post allografting may potentially increase the risk of treatment-emergent graft versus host disease. We herein report the clinical course of a patient who experienced multiple relapses of HL post allogeneic stem cell transplantation. He failed several treatment modalities but he responded to escalating doses of the PD-1 inhibitor nivolumab, given at two different treatment time points, also demonstrating minimal and easily manageable toxicity.<\/jats:p>","DOI":"10.4081\/hr.2021.8780","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T13:55:25Z","timestamp":1614952525000},"page":"8780","source":"Crossref","is-referenced-by-count":1,"title":["Repeated Courses of Escalating Doses of Nivolumab in Refractory Hodgkin Lymphoma with Recurrent Relapses Post Allografting: A Safe and Effective Treatment Approach"],"prefix":"10.3390","volume":"13","author":[{"given":"Panayotis","family":"Kaloyannidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshrak","family":"Al Shaibani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif","family":"Moinnudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Al Anezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Al Hashmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bmt.2016.129","article-title":"Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.bbmt.2014.05.024","article-title":"Bendamustine combined with donor lymphocytes infusion in Hodgkin\u2019s lymphoma relapsing after allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Sala","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow- Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune check-point blockade in hematologic malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing Immune Checkpoint-Blocking Antibody Side Effects","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1038\/bcj.2015.58","article-title":"PD- 1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation","volume":"5","author":"Kong","year":"2015","journal-title":"Blood Cancer J"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1158\/0008-5472.CAN-11-0108","article-title":"PD- 1\/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation","volume":"71","author":"Norde","year":"2011","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-015-0189-2","article-title":"T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment","volume":"8","author":"Schnorfeil","year":"2015","journal-title":"J Hematol Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.V128.22.1110.1110","article-title":"Checkmate 205 update with minimum 12-Month follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed\/Refractory Classical Hodgkin Lymphoma","volume":"128","author":"Timmerman","year":"2016","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of Nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-017-0211-z","article-title":"PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation","volume":"5","author":"Godfrey","year":"2017","journal-title":"J Immunother Cancer"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow- Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref19","first-page":"275","article-title":"Optimizing check-point blockade as a Treatment for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"130","author":"Davids","year":"2017","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-017-2181-9","article-title":"Successful treatment with low-dose Nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"106","author":"Onizuka","year":"2017","journal-title":"Int J Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","volume":"132","author":"Herbaux","year":"2018","journal-title":"Blood"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/download\/8780\/8534","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2038-8330\/13\/1\/8780\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T07:35:15Z","timestamp":1645601715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/13\/1\/8780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["hr.2021.8780"],"URL":"https:\/\/doi.org\/10.4081\/hr.2021.8780","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]}}}